vs
Side-by-side financial comparison of Porch Group, Inc. (PRCH) and Travere Therapeutics, Inc. (TVTX). Click either name above to swap in a different company.
Travere Therapeutics, Inc. is the larger business by last-quarter revenue ($129.7M vs $121.1M, roughly 1.1× Porch Group, Inc.). On growth, Porch Group, Inc. posted the faster year-over-year revenue change (100.0% vs 73.4%). Over the past eight quarters, Travere Therapeutics, Inc.'s revenue compounded faster (77.0% CAGR vs 26.4%).
Porch is a website that tries to connect homeowners with local home improvement contractors. The site features advice articles, cost guide, and online booking for over 160 home projects.
Travere Therapeutics, Inc. is a global biopharmaceutical firm developing and commercializing innovative therapies for patients with rare, serious, life-threatening diseases. Its key segments cover rare nephrology, hepatology and metabolic disorders, serving markets across North America, Europe and other global regions.
PRCH vs TVTX — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $121.1M | $129.7M |
| Net Profit | $-4.7M | — |
| Gross Margin | 52.7% | 98.0% |
| Operating Margin | 34.7% | -25.0% |
| Net Margin | -3.9% | — |
| Revenue YoY | 100.0% | 73.4% |
| Net Profit YoY | 2.0% | — |
| EPS (diluted) | $-0.04 | $0.04 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $121.1M | — | ||
| Q4 25 | $112.3M | $129.7M | ||
| Q3 25 | $115.1M | $164.9M | ||
| Q2 25 | $107.0M | $114.4M | ||
| Q1 25 | $84.5M | $81.7M | ||
| Q4 24 | $75.3M | $74.8M | ||
| Q3 24 | $77.7M | $62.9M | ||
| Q2 24 | $75.9M | $54.1M |
| Q1 26 | $-4.7M | — | ||
| Q4 25 | $-3.5M | — | ||
| Q3 25 | $-10.9M | $25.7M | ||
| Q2 25 | $2.6M | $-12.8M | ||
| Q1 25 | $8.4M | $-41.2M | ||
| Q4 24 | $30.5M | — | ||
| Q3 24 | $14.4M | $-54.8M | ||
| Q2 24 | $-64.3M | $-70.4M |
| Q1 26 | 52.7% | — | ||
| Q4 25 | 99.5% | 98.0% | ||
| Q3 25 | 75.6% | 99.0% | ||
| Q2 25 | 70.9% | 98.7% | ||
| Q1 25 | 77.4% | 94.3% | ||
| Q4 24 | — | 96.6% | ||
| Q3 24 | 79.4% | 97.4% | ||
| Q2 24 | 22.1% | 96.2% |
| Q1 26 | 34.7% | — | ||
| Q4 25 | 14.7% | -25.0% | ||
| Q3 25 | 14.2% | 15.1% | ||
| Q2 25 | 4.7% | -11.1% | ||
| Q1 25 | -1.5% | -52.2% | ||
| Q4 24 | 33.3% | -81.2% | ||
| Q3 24 | -3.2% | -89.3% | ||
| Q2 24 | -69.2% | -125.1% |
| Q1 26 | -3.9% | — | ||
| Q4 25 | -3.1% | — | ||
| Q3 25 | -9.4% | 15.6% | ||
| Q2 25 | 2.4% | -11.1% | ||
| Q1 25 | 9.9% | -50.4% | ||
| Q4 24 | 40.5% | — | ||
| Q3 24 | 18.5% | -87.1% | ||
| Q2 24 | -84.8% | -130.1% |
| Q1 26 | $-0.04 | — | ||
| Q4 25 | $0.00 | $0.04 | ||
| Q3 25 | $-0.10 | $0.28 | ||
| Q2 25 | $0.00 | $-0.14 | ||
| Q1 25 | $0.07 | $-0.47 | ||
| Q4 24 | $0.34 | $-0.71 | ||
| Q3 24 | $0.12 | $-0.70 | ||
| Q2 24 | $-0.65 | $-0.91 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $68.4M | $93.0M |
| Total DebtLower is stronger | $391.3M | — |
| Stockholders' EquityBook value | $26.3M | $114.8M |
| Total Assets | $806.6M | $605.2M |
| Debt / EquityLower = less leverage | 14.87× | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $68.4M | — | ||
| Q4 25 | $57.3M | $93.0M | ||
| Q3 25 | $85.0M | $110.9M | ||
| Q2 25 | $79.8M | $75.2M | ||
| Q1 25 | $70.4M | $61.9M | ||
| Q4 24 | $191.7M | $58.5M | ||
| Q3 24 | $238.6M | $36.4M | ||
| Q2 24 | $308.4M | $32.3M |
| Q1 26 | $391.3M | — | ||
| Q4 25 | $392.8M | — | ||
| Q3 25 | $387.1M | — | ||
| Q2 25 | $394.1M | — | ||
| Q1 25 | $409.2M | — | ||
| Q4 24 | $403.9M | — | ||
| Q3 24 | $399.0M | — | ||
| Q2 24 | $436.8M | — |
| Q1 26 | $26.3M | — | ||
| Q4 25 | $-24.6M | $114.8M | ||
| Q3 25 | $-27.9M | $73.6M | ||
| Q2 25 | $-29.3M | $32.7M | ||
| Q1 25 | $-52.4M | $32.8M | ||
| Q4 24 | $-43.2M | $59.1M | ||
| Q3 24 | $-77.0M | $-30.5M | ||
| Q2 24 | $-101.9M | $15.1M |
| Q1 26 | $806.6M | — | ||
| Q4 25 | $797.4M | $605.2M | ||
| Q3 25 | $787.7M | $538.6M | ||
| Q2 25 | $770.7M | $555.3M | ||
| Q1 25 | $802.3M | $548.8M | ||
| Q4 24 | $814.0M | $594.1M | ||
| Q3 24 | $867.3M | $504.4M | ||
| Q2 24 | $876.1M | $551.1M |
| Q1 26 | 14.87× | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $60.7M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $1.2M | $60.7M | ||
| Q3 25 | $40.8M | $14.3M | ||
| Q2 25 | $35.6M | $5.0M | ||
| Q1 25 | $-11.2M | $-42.2M | ||
| Q4 24 | $-26.6M | $-35.7M | ||
| Q3 24 | $12.4M | $-42.5M | ||
| Q2 24 | $-26.0M | $-40.2M |
| Q1 26 | — | — | ||
| Q4 25 | $1.1M | — | ||
| Q3 25 | $40.7M | $14.2M | ||
| Q2 25 | $35.4M | — | ||
| Q1 25 | $-11.2M | — | ||
| Q4 24 | $-26.8M | — | ||
| Q3 24 | $12.2M | — | ||
| Q2 24 | $-26.0M | $-40.3M |
| Q1 26 | — | — | ||
| Q4 25 | 1.0% | — | ||
| Q3 25 | 35.4% | 8.6% | ||
| Q2 25 | 33.0% | — | ||
| Q1 25 | -13.3% | — | ||
| Q4 24 | -35.6% | — | ||
| Q3 24 | 15.7% | — | ||
| Q2 24 | -34.3% | -74.5% |
| Q1 26 | — | — | ||
| Q4 25 | 0.1% | — | ||
| Q3 25 | 0.1% | 0.1% | ||
| Q2 25 | 0.2% | — | ||
| Q1 25 | 0.1% | — | ||
| Q4 24 | 0.3% | — | ||
| Q3 24 | 0.3% | 0.0% | ||
| Q2 24 | 0.1% | 0.2% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 0.56× | ||
| Q2 25 | 13.79× | — | ||
| Q1 25 | -1.33× | — | ||
| Q4 24 | -0.87× | — | ||
| Q3 24 | 0.86× | — | ||
| Q2 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
PRCH
Segment breakdown not available.
TVTX
| FILSPARI | $103.3M | 80% |
| Tiopronin Products | $23.3M | 18% |
| License | $3.1M | 2% |
